Dr. Reddy'S Laboratories (RDY) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $852.6M
- Gross margin
- 50.02%
- Net income (quarter)
- $45.9M
- Net margin
- 9.72%
- Return on equity
- 8.32%
- Book value per share
- $4.85
- Price to book
- 2.60
- Debt to assets
- 32.78%
- Payout ratio
- 17.05%
- Dividend yield
- 0.50%
Company profile
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Frequently asked questions
Is Dr. Reddy'S Laboratories (RDY) profitable?
Yes. Dr. Reddy'S Laboratories earned $334.1M in net income over the trailing twelve months, a net margin of 9.72%.
How much revenue does Dr. Reddy'S Laboratories (RDY) make?
Dr. Reddy'S Laboratories generated $3.4B in revenue over the trailing twelve months, down 14.45% year over year.
What is RDY's P/E ratio?
Dr. Reddy'S Laboratories trades at 31.5 times trailing twelve-month earnings, on an EPS of $0.41.
How do I buy stock in Dr. Reddy'S Laboratories (RDY)?
RDY trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.
